Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

NCT03066427 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Carcinoma

Interventions

DRUG: Sunitinib

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]